OverviewSuggest Edit
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of oncology products including candidates intended to treat specific genetic and epigenetic drivers of cancer in selected subsets of cancer patients with unmet needs. The Company's clinical pipeline consists of three product candidates: glesatinib, sitravatinib and mocetinostat. Both glesatinib and sitravatinib are orally-bioavailable, spectrum-selective kinase inhibitors with distinct target profiles that are in development for the treatment of patients with NSCLC and other solid tumors.
| Type | Public | |
| Founded | 2013 | |
| HQ | San Diego, US | Map |
| Website | mirati.com |
Recent NewsAll News
- Mirati Therapeutics To Present At Upcoming Healthcare Conferences
- Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day
- Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
- Mirati Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference
Key People/Management at Mirati Therapeutics
Charles M. Baum
President and CEO
Isan Chen
Chief Medical and Development Officer
Chris Lemasters
Chief Business Officer
James Christensen
Senior Vice President and Chief Scientific Officer
Jamie Donadio
Senior Vice President and Chief Financial Officer
Perry C. Johnston
Vice President, Chief Legal and Compliance Officer, and Corporate Secretary
Report incorrect company information
Mirati Therapeutics Office Locations
Mirati Therapeutics has an office in San Diego
San Diego, US (HQ)
9393 Towne Centre Dr #200
Report incorrect company information
Mirati Therapeutics Financials and Metrics
Mirati Therapeutics Revenue
Mirati Therapeutics's revenue was reported to be $12.93 m in FY, 2018
| USD | |
|---|---|
Revenue (FY, 2018) | 12.9m |
Net income (FY, 2018) | (98.4m) |
EBIT (FY, 2018) | (102.6m) |
Market capitalization (21-Mar-2019) | 2.7b |
Closing stock price (21-Mar-2019) | 75.4 |
Cash (31-Dec-2018) | 32.7m |
Mirati Therapeutics's current market capitalization is $2.7 b.
Annual
Quarterly
| USD | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q1, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 9.5m | |||||||||||
General and administrative expense | 2.4m | 2.9m | 3.5m | 3.8m | 4.2m | 4.2m | 4.1m | 3.8m | 3.5m | 3.7m | 3.7m | 5.2m |
R&D expense | 5.2m | 7.2m | 7.0m | 8.2m | 11.3m | 14.6m | 18.0m | 18.4m | 16.1m | 14.4m | 15.0m | 19.7m |
Operating expense total | 8.0m | 10.1m | 10.5m | 12.0m | 15.5m | 18.7m | 22.1m | 22.2m | 19.6m | 18.1m | 18.6m | 24.8m |
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q1, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 7.6m | 8.3m | 8.5m | 4.9m | 14.3m | 13.4m | 109.9m | 34.6m | 24.5m | 19.8m | 29.8m | 20.0m | 20.6m |
Current Assets | 17.0m | 56.0m | 49.2m | 40.3m | 71.2m | 60.9m | 141.0m | 109.9m | 93.0m | 75.5m | 107.9m | 92.3m | 153.1m |
PP&E | 427.0k | 275.0k | 479.0k | 524.0k | 667.0k | 693.0k | 639.0k | 601.0k | 558.0k | 537.0k | 638.0k | 618.0k | 484.0k |
Total Assets | 18.0m | 56.3m | 49.7m | 41.3m | 72.2m | 61.9m | 143.7m | 112.5m | 96.0m | 79.2m | 110.8m | 95.0m | 154.5m |
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q1, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (13.7m) | (11.0m) | (33.3m) | (11.9m) | (27.4m) | (46.1m) | (21.9m) | (44.0m) | (63.4m) | (17.8m) | (36.2m) | (14.7m) | |
Depreciation and Amortization | 105.0k | 154.0k | 100.0k | 153.0k | 101.0k | 139.0k | 91.0k | 41.0k | |||||
Accounts Payable | 1.3m | 111.0k | |||||||||||
Cash From Operating Activities | (35.8m) | (7.9m) |
| USD | Y, 2018 |
|---|---|
Financial Leverage | 1.1 x |
Mirati Therapeutics Operating Metrics
| FY, 2016 | |
|---|---|
Patents Issued | 32 |
Patents Pending | 1 |
Report incorrect company information
Mirati Therapeutics Online and Social Media Presence
142 Twitter followers
Mirati Therapeutics has 142 Twitter Followers. The number of followers has increased 2.2% month over month and increased 5.8% quarter over quarter
Report incorrect company information
Mirati Therapeutics News and Updates
March 05, 2019
Mirati Therapeutics To Present At Upcoming Healthcare Conferences
SAN DIEGO, March 5, 2019 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at two upcoming healthcare conferences. Cowen 39th Annual Healthcare Conference in Boston on Tuesday, March 12th at 11:20 a.m. ET/ 8:20 a.m. PT. Oppenheimer 29th...
February 07, 2019
Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day
SAN DIEGO, Feb. 7, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in the Guggenheim Healthcare Talks Idea Forum & Oncology Day in New York on Thursday, February 14th at 11:00 a.m. ET/ 8:00 a.m. PT. Chris...
January 17, 2019
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
SAN DIEGO, Jan. 16, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 1,612,903 shares of its common stock at a price to the public of $62.00 per share. The aggregate gross proceeds from this offering are...
January 02, 2019
Mirati Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 2, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9th at 8:00 a.m. PST/ 11:00 a.m. EST. Charles M. Baum, M.D....
December 20, 2018
Mirati Therapeutics Added To NASDAQ Biotechnology Index
SAN DIEGO, Dec. 20, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: ^NBI). The Company's addition to the Index will become...
December 10, 2018
Mirati Therapeutics Announces The Appointment Of Maya Martinez-Davis To The Board Of Directors
SAN DIEGO, Dec. 10, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the appointment of Maya Martinez-Davis to the Company's Board of Directors, effective immediately. Ms. Martinez-Davis is the President of...
Report incorrect company information
Mirati Therapeutics Blogs
February 28, 2019
Mirati Therapeutics Reports Fourth Quarter Financial Results
Mirati Therapeutics Reports Fourth Quarter Financial Results
Content Import
Thu, 02/28/2019 - 16:26
Mirati Therapeutics Reports Fourth Quarter Financial Results
February 28, 2019
This release is a backfill from a News Wire
Earnings
…
February 19, 2019
Mirati Therapeutics Announces The Appointment Of Faheem Hasnain As Chairman Of The Board Of Directors
SAN DIEGO , Feb. 19, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the appointment of Faheem Hasnain as Chairman of the Board, effective February 15, 2019 . Dr. Rodney Lappe Ph.D.
February 07, 2019
Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day
SAN DIEGO , Feb. 7, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in the Guggenheim Healthcare Talks Idea Forum & Oncology Day in New York on Thursday, February 14 th at 11:00 a.m. ET / 8:00 a.m. PT .
January 22, 2019
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
SAN DIEGO , Jan. 22, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 1,854,838 shares of its common stock at a public offering price of $62 .00 per share.
January 16, 2019
Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
Content Import
Wed, 01/16/2019 - 16:04
Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
January 16, 2019
This release is a backfill from a News Wire
Ge…
January 15, 2019
Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor
Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor
Content Import
Tue, 01/15/2019 - 16:25
Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor
…
Mirati Therapeutics Frequently Asked Questions
When was Mirati Therapeutics founded?
Mirati Therapeutics was founded in 2013.
Who are Mirati Therapeutics key executives?
Mirati Therapeutics's key executives are Charles M. Baum, Isan Chen and Chris Lemasters.
How many employees does Mirati Therapeutics have?
Mirati Therapeutics has 51 employees.
What is Mirati Therapeutics revenue?
Latest Mirati Therapeutics annual revenue is $12.9 m.
What is Mirati Therapeutics revenue per employee?
Latest Mirati Therapeutics revenue per employee is $253.5 k.
Who are Mirati Therapeutics competitors?
Competitors of Mirati Therapeutics include OncoStem Diagnostics, Heidelberg Pharma and MEI Pharma.
Where is Mirati Therapeutics headquarters?
Mirati Therapeutics headquarters is located at 9393 Towne Centre Dr #200, San Diego.
Where are Mirati Therapeutics offices?
Mirati Therapeutics has an office in San Diego.
How many offices does Mirati Therapeutics have?
Mirati Therapeutics has 1 office.